This Article Full Text Full Text (PDF) All Versions of this Article: 112/14/2102    most recent CIRCULATIONAHA.105.550715v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ndrepepa, G. Articles by Kastrati, A. Search for Related Content PubMed PubMed Citation Articles by Ndrepepa, G. Articles by Kastrati, A. Related Collections Catheter-based coronary interventions: stents Chronic ischemic heart disease Related Article

(Circulation. 2005;112:2102-2107.)
© 2005 American Heart Association, Inc.

Coronary Heart Disease

Prognostic Value of N-Terminal Pro–Brain Natriuretic Peptide in Patients With Chronic Stable Angina

Gjin Ndrepepa, MD; Siegmund Braun, MD; Kathrin Niemöller, MD; Julinda Mehilli, MD; Nicolas von Beckerath, MD; Olga von Beckerath, MD; Wolfgang Vogt, MD; Albert Schömig, MD; Adnan Kastrati, MD

From the Klinik für Herz- und Kreislauferkrankungen (G.N., K.N., J.M., N.v.B., O.v.B., A.S., A.K.) und Institut für Laboratoriumsmedizin (S.B., W.V.), Deutsches Herzzentrum München and 1 Medizinische Klinik Klinikum rechts der Isar (A.S.), Technische Universität München, Munich, Germany.

Correspondence to Adnan Kastrati, MD, Deutsches Herzzentrum, Lazarettstrasse 36, 80636 München, Germany. E-mail kastrati{at}dhm.mhn.de

Received October 14, 2004; de novo received March 21, 2005; revision received June 29, 2005; accepted July 6, 2005.

Background— Patients with chronic stable angina are poorly characterized in terms of biomarkers that help in the assessment of prognosis. We investigated whether plasma levels of N-terminal pro–brain natriuretic peptide (NT-proBNP) may be used as a prognostic marker in patients with chronic stable angina treated with coronary stenting.

Methods and Results— Plasma levels of NT-proBNP were measured in 1059 patients with chronic stable angina and coronary angiographic confirmation of significant coronary artery disease. The primary end point of the study was mortality. After a median of 3.6 years (interquartile range, 3.3 to 4.5 years), there were 106 deaths. Kaplan-Meier estimates of 5-year mortality were 4.7% in the first quartile, 7.8% in the second quartile, 11.4% in the third quartile, and 32.7% in the fourth quartile of NT-proBNP (P<0.001). A Cox proportional hazards model showed that NT-proBNP was the strongest correlate of mortality (adjusted hazards ratio [HR], 5.83 [95% confidence interval: 2.07 to 16.44] for the fourth versus the first quartile). A similar prognostic value of NT-proBNP was demonstrated for cardiovascular mortality (HR, 5.98 [1.55 to 23.13] for the fourth versus the first quartile) and for patients with New York Heart Association class I and II (HR, 6.03 [2.07 to 17.52] for the fourth versus the first quartile).

Conclusions— Circulating levels of NT-proBNP are a strong prognostic biomarker for patients with chronic stable angina.

Key Words: angina • mortality • natriuretic peptides • prognosis

Related Article:

Issue Highlights
Circulation 2005 112: 2077-2078. [Extract] [Full Text]

This article has been cited by other articles:

				E. Di Angelantonio, R. Chowdhury, N. Sarwar, K. K. Ray, R. Gobin, D. Saleheen, A. Thompson, V. Gudnason, N. Sattar, and J. Danesh B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies Circulation, December 1, 2009; 120(22): 2177 - 2187. [Abstract] [Full Text] [PDF]

				American College of Cardiology Foundation, American Heart Association, American College of Physicians Task Force on Compe, American Academy of Neurology, American Association of Cardiovascular and Pulmona, American College of Preventive Medicine, American Diabetes Association, American Society of Hypertension, Association of Black Cardiologists, National Lipid Association, et al. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1336 - 1363. [Full Text] [PDF]

				WRITING COMMITTEE MEMBERS, C. N. Bairey Merz, M. J. Alberts, G. J. Balady, C. M. Ballantyne, K. Berra, H. R. Black, R. S. Blumenthal, M. H. Davidson, S. B. Fazio, et al. ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease: A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): Developed in Collaboration With the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association Circulation, September 29, 2009; 120(13): e100 - e126. [Full Text] [PDF]

				W. Derer, E. S. Barnathan, E. Safak, P. Agarwal, H. Heidecke, M. Mockel, M. Gross, C. Oezcelik, R. Dietz, and R. Dechend Vitronectin Concentrations Predict Risk in Patients Undergoing Coronary Stenting Circ Cardiovasc Interv, February 1, 2009; 2(1): 14 - 19. [Abstract] [Full Text] [PDF]

				S. K. Prasad, A. Clerk, T. E. Cullingford, A. W.Y. Chen, T. J. Kemp, T. M. Cannell, M. R. Cowie, and M. Petrou Gene expression profiling of human hibernating myocardium: Increased expression of B-type natriuretic peptide and proenkephalin in hypocontractile vs normally-contracting regions of the heart Eur J Heart Fail, December 1, 2008; 10(12): 1177 - 1180. [Abstract] [Full Text] [PDF]

				T. Omland, M. S. Sabatine, K. A. Jablonski, M. M. Rice, J. Hsia, R. Wergeland, S. Landaas, J. L. Rouleau, M. J. Domanski, C. Hall, et al. Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial J. Am. Coll. Cardiol., July 17, 2007; 50(3): 205 - 214. [Abstract] [Full Text] [PDF]

				Stable angina who needs revascularisation? DTB, February 1, 2007; 45(2): 12 - 16. [Abstract] [Full Text] [PDF]

				K. Bibbins-Domingo, R. Gupta, B. Na, A. H. B. Wu, N. B. Schiller, and M. A. Whooley N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP), Cardiovascular Events, and Mortality in Patients With Stable Coronary Heart Disease JAMA, January 10, 2007; 297(2): 169 - 176. [Abstract] [Full Text] [PDF]

				D. Rothenbacher, W. Koenig, and H. Brenner Comparison of N-Terminal Pro-B-Natriuretic Peptide, C-Reactive Protein, and Creatinine Clearance for Prognosis in Patients With Known Coronary Heart Disease Arch Intern Med, December 11, 2006; 166(22): 2455 - 2460. [Abstract] [Full Text] [PDF]

				P. Minoretti, C. Falcone, M. Calcagnino, E. Emanuele, M. P. Buzzi, E. Coen, and D. Geroldi Prognostic significance of plasma osteopontin levels in patients with chronic stable angina Eur. Heart J., April 1, 2006; 27(7): 802 - 807. [Abstract] [Full Text] [PDF]